NEW YORK (Reuters Health) – In patients with non-small-cell lung cancer (NSCLC), exhaled-breath analysis with an “electronic nose” (eNose) may be able to monitor response to immune-checkpoint...

Patients with resectable non–small cell lung cancer (NSCLC) often receive treatment before they undergo surgery. For such patients who achieve a pathologic complete response (pCR), the chances of survival...

ZURICH (Reuters) – Novartis’s uphill struggle to re-purpose its inflammation drug Ilaris took another hit when the Swiss drugmaker said on Tuesday that the medicine failed to boost overall...